Norway pharmacy online: Kjøp av viagra uten resept i Norge på nett.

Jeg kan anbefale en god måte for å øke potens - Cialis. Fungerer mye bedre kjøp priligy Alltid interessant, disse pillene og andre ting i Generelle virkelig har helse til å handle.

Material Safety Data Sheet

* * Section 1 - Chemical Product and Company Identification * * *

Chemical Name: Spectral.DNC-L
Product Use: Hair Growth Stimulating Lotion
* * * Section 2 - Composition / Information on Ingredients * * *
Component Information/Information on Non-Hazardous Components:
This product is non-hazardous and is not transport regulated.
* * * Section 3 - Hazard Identification * * *
Emergency Overview
No particular hazards known.
Potential Health Effects: Eyes
This product will cause irritation to the eyes.
Potential Health Effects: Systemic overexposure
Potential Health Effects: Ingestion
Contact a physician or poison control center.
Potential Health Effects: Inhalation
Remove from exposure. HMIS Ratings: Health: 1 Fire: 1 Reactivity: 0 Pers. Prot.: None required.
Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate 3 = Serious 4 = Severe * = Chronic hazard
*** Section4- FirstAid Measures ***
First Aid: Eyes
Seek medical attention.
First Aid: Skin
Wash with soap and water. Remove contaminated clothing.
First Aid: Ingestion
If material is swallowed, get medical attention or contact poison control center.
First Aid: Inhalation Remove from exposure.
* * * Section 5 - Fire Fighting Measures * * *
General Fire Hazards
Upper Flammable Limit (UFL): Not determined
Lower Flammable Limit (LFL): Not determined
Method Used: N/E

Material Safety Data Sheet
Flash Point: ~100oC
Flammability Classification:
Auto Ignition: Not determined Hazardous Combustion Products Oxides of carbon and sulfur.
Extinguishing Media Dry chemical, foam, carbon dioxide, water fog.
Fire Fighting Equipment/Instructions
NFPA Ratings: Health: 1 Fire: 1 Reactivity: 0 Hazard Scale: 0 = Minimal 1 = Slight 2 = Moderate 3
= Serious 4 = Severe
* * * Section 6 - Accidental Release Measures * * *
Containment Procedures Absorb spill with inert material.
Clean-Up Procedures Absorb spill with inert material.
Shovel material into appropriate container for disposal.
Flush small residuals to the drain for normal biological wastewater treatment.
Evacuation Procedures: None.
Special Procedures Spilled product may create slippery conditions.
Exercise caution in spill area.
*** Section7 - Handling and Storage ***
Handling Procedures: No special requirements.
Storage Procedures Protect from freezing or extreme heat.
* * * Section 8 - Exposure Controls / Personal Protection * * *
Exposure Guidelines

A: General Product Information OSHA exempt.
B: Component Exposure Limits: No information is available.

Engineering Controls: None necessary.

PERSONAL PROTECTIVE EQUIPMENT Personal Protective Equipment: Eyes/Face Avoid eye
contact. Personal Protective Equipment: Skin Avoid skin contact other then for intended use.
Personal Protective Equipment: Respiratory None. Personal Protective Equipment: General Obey
reasonable safety precautions and practice good housekeeping.
* * * Section 9 - Physical & Chemical Properties * * *

Physical State:
Vapor Pressure:
Boiling Point:
Solubility (H2O):
Material Safety Data Sheet
Vapor Density:
Melting Point:
Specific Gravity:

* * * Section 10 - Chemical Stability & Reactivity Information * * *
Chemical Stability
Stable under usual application conditions.
Chemical Stability: Conditions to Avoid
Hazardous Decomposition
Oxides of carbon and sulfur.
Hazardous Polymerization
Hazardous polymerization will not occur.
* * * Section 11 - Toxicological Information * * *
Acute and Chronic Toxicity
A:EYE IRRITATION: Minimally irritating.
B. SKIN LD50 (RAT): >2007 mg/kg (minoxidil)
C. ORAL LD50 (MOUSE): 2,457 mg/kg (minoxidil)
A: Genotoxicity: Minoxidil was not mutagenic in the Ames test or the rat micronucleus test.
B: Carcinogenicity No evidence for carcinogenicity was detected in rats or rabbits when minoxidil
was applied to the skin for up to 1 year.
* * * Section 12 - Ecological Information * * *
A: General Product Information: No information available.
B: Component Analysis - Ecotoxicity - Aquatic Toxicity: No information available,
C: Environmental Fate: No information available for the product.
* * * Section 13 - Disposal Considerations * * *
US EPA Waste Number & Descriptions
A: General Product Information
Controlled release of diluted product into a biological wastewater treatment plant.
B: Component Waste Numbers
No EPA Waste Numbers are applicable for this product's components. Disposal Instructions Dispose of
waste material according to Local, State, Federal, and Provincial Environmental Regulations.
Material Safety Data Sheet
* * * Section 14 - Transportation Information * * *

International Transportation Regulations This product is not regulated as a hazardous material by
the United States (DOT) or Canadian (TDG) transportation regulations.
* * * Section 15 - Other Information * * *
Other Information
Reasonable care has been taken in the preparation of this information, but the
manufacturer makes no warranty of merchantability or any other warranty, expressed or
implied, with respect to this information. The manufacturer makes no representations
and assumes no liability for any direct, incidental or consequential damages resulting
from its use.


Ilse degreef - sep 2013

Curriculum Vitae Ilse Degreef Geboortedatum: Functie: MEDICAL TRAINING 1997 Medical Doctor, University of Leuven, Belgium Orthopaedic Surgeon, University of Leuven, Belgium Hand surgeon, University of Leuven, Belgium PhD Biomedical sciences, University of Leuven, Belgium Doctor in Biomedical Science, Leuven University Hospitals, Leuven, Belgium Professor in Orthopaedi

Corel office document

MEDICAL REPORT OF DOCTOR ALBERT BENCHABBAT ON EXAMINATION OF EMANUEL ZELTSER IN THE KGB PRISON IN MINSK, BELARUS (JUNE 26, 2008) 1. The Doctor’s Credentials I am Albert Benchabbat, MD, and I am licensed to practice medicine in the States of New York and Florida. Ipractice medicine for about 20 years and am certified by the American Board of Internal Medicine. 2. The Patient’s

Copyright © 2010-2014 Drug Shortages pdf